Recruiting Clinical Trials

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

By April 24, 2017 No Comments


Solid Tumors|Triple-Negative Breast Cancer|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Mesothelioma|Fumarate Hydratase (FH)-Deficient Tumors|Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)|Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors|Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations|Tumors Harboring Amplifications in the cMyc Gene

Estimated Enrollment: 205

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: CX-839-001

Study First Received: February 14, 2014

Last Updated: August 18, 2016

Estimated Primary Completion Date: June 2017


Primary Outcome Measures:

Safety and tolerability of CB-839: Incidence of adverse events|Pharmacokinetics: Area under the Curve (AUC) of CB-839 concentration in blood|Pharmacodynamics: % inhibition of glutaminase in blood|Clinical activity: Change in tumor volume from baseline

Sponsors and Collaborators:

Calithera Biosciences, Inc

Website Link:

Leave a Reply

Call Now ButtonCall Now